Market News
Sun Pharma guides for slower FY27 growth amid regulatory, macro challenges
Published 2026-05-26 · Bazaar Watch Research
- Sun Pharma projects high single-digit revenue growth for FY27.
- This follows an 11.9% revenue increase reported for FY26.
- The company faces ongoing regulatory challenges and compliance issues.
- Sun Pharma is expanding its innovative portfolio and targeting the obesity-drug market.
- Sun Pharma shareholders may see slower near-term growth prospects.
- Investors in the Indian pharmaceutical sector should monitor regulatory impacts.
- Review Sun Pharma's long-term strategy, especially its innovative pipeline.
- Consider diversifying your portfolio beyond single pharmaceutical stocks.
